1
|
Heid I, Trajkovic-Arsic M, Lohöfer F, Kaissis G, Harder FN, Mayer M, Topping GJ, Jungmann F, Crone B, Wildgruber M, Karst U, Liotta L, Algül H, Yen HY, Steiger K, Weichert W, Siveke JT, Makowski MR, Braren RF. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization. Eur J Nucl Med Mol Imaging 2022; 50:115-129. [PMID: 36074156 DOI: 10.1007/s00259-022-05930-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 08/01/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is a molecularly heterogeneous tumor entity with no clinically established imaging biomarkers. We hypothesize that tumor morphology and physiology, including vascularity and perfusion, show variations that can be detected by differences in contrast agent (CA) accumulation measured non-invasively. This work seeks to establish imaging biomarkers for tumor stratification and therapy response monitoring in PDAC, based on this hypothesis. METHODS AND MATERIALS Regional CA accumulation in PDAC was correlated with tumor vascularization, stroma content, and tumor cellularity in murine and human subjects. Changes in CA distribution in response to gemcitabine (GEM) were monitored longitudinally with computed tomography (CT) Hounsfield Units ratio (HUr) of tumor to the aorta or with magnetic resonance imaging (MRI) ΔR1 area under the curve at 60 s tumor-to-muscle ratio (AUC60r). Tissue analyses were performed on co-registered samples, including endothelial cell proliferation and cisplatin tissue deposition as a surrogate of chemotherapy delivery. RESULTS Tumor cell poor, stroma-rich regions exhibited high CA accumulation both in human (meanHUr 0.64 vs. 0.34, p < 0.001) and mouse PDAC (meanAUC60r 2.0 vs. 1.1, p < 0.001). Compared to the baseline, in vivo CA accumulation decreased specifically in response to GEM treatment in a subset of human (HUr -18%) and mouse (AUC60r -36%) tumors. Ex vivo analyses of mPDAC showed reduced cisplatin delivery (GEM: 0.92 ± 0.5 mg/g, vs. vehicle: 3.1 ± 1.5 mg/g, p = 0.004) and diminished endothelial cell proliferation (GEM: 22.3% vs. vehicle: 30.9%, p = 0.002) upon GEM administration. CONCLUSION In PDAC, CA accumulation, which is related to tumor vascularization and perfusion, inversely correlates with tumor cellularity. The standard of care GEM treatment results in decreased CA accumulation, which impedes drug delivery. Further investigation is warranted into potentially detrimental effects of GEM in combinatorial therapy regimens.
Collapse
Affiliation(s)
- Irina Heid
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany.
| | - Marija Trajkovic-Arsic
- Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany.,Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany
| | - Fabian Lohöfer
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany
| | - Georgios Kaissis
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany.,Department of Computing, Imperial College London, London, SW7 2AZ, UK.,School of Medicine, Institute for Artificial Intelligence in Medicine and Healthcare, Technical University of Munich, Munich, Germany
| | - Felix N Harder
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany
| | - Moritz Mayer
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany
| | - Geoffrey J Topping
- School of Medicine, Department of Nuclear Medicine, Technical University of Munich, Munich, Germany
| | - Friderike Jungmann
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany
| | - Barbara Crone
- Institute of Inorganic and Analytical Chemistry, University of Muenster, Muenster, Germany
| | - Moritz Wildgruber
- Institute of Clinical Radiology, University Hospital Muenster, Muenster, Germany.,Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, University of Muenster, Muenster, Germany
| | - Lucia Liotta
- School of Medicine, Clinic and Policlinic of Internal Medicine II, Technical University of Munich, Munich, Germany
| | - Hana Algül
- Comprehensive Cancer Center Munich at the Klinikum rechts der Isar (CCCMTUM), Technical University of Munich, Munich, Germany
| | - Hsi-Yu Yen
- School of Medicine, Institute of Pathology, Technical University of Munich, Munich, Germany
| | - Katja Steiger
- School of Medicine, Institute of Pathology, Technical University of Munich, Munich, Germany
| | - Wilko Weichert
- School of Medicine, Institute of Pathology, Technical University of Munich, Munich, Germany.,German Cancer Consortium (DKTK, partner Site Munich), Munich, Germany
| | - Jens T Siveke
- Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany.,Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany
| | - Marcus R Makowski
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany
| | - Rickmer F Braren
- School of Medicine, Institute of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany. .,German Cancer Consortium (DKTK, partner Site Munich), Munich, Germany.
| |
Collapse
|
2
|
Liotta L, Lange S, Maurer HC, Olive KP, Braren R, Pfarr N, Burger S, Muckenhuber A, Jesinghaus M, Steiger K, Weichert W, Friess H, Schmid R, Algül H, Jost PJ, Ramser J, Fischer C, Quante AS, Reichert M, Quante M. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. JCI Insight 2021; 6:141532. [PMID: 33764904 PMCID: PMC8119201 DOI: 10.1172/jci.insight.141532] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 03/17/2021] [Indexed: 12/24/2022] Open
Abstract
BACKGROUNDPancreatic cancer is one of the deadliest cancers, with low long-term survival rates. Despite recent advances in treatment, it is important to identify and screen high-risk individuals for cancer prevention. Familial pancreatic cancer (FPC) accounts for 4%-10% of pancreatic cancers. Several germline mutations are related to an increased risk and might offer screening and therapy options. In this study, we aimed to identity of a susceptibility gene in a family with FPC.METHODSWhole exome sequencing and PCR confirmation was performed on the surgical specimen and peripheral blood of an index patient and her sister in a family with high incidence of pancreatic cancer, to identify somatic and germline mutations associated with familial pancreatic cancer. Compartment-specific gene expression data and immunohistochemistry were also queried.RESULTSThe identical germline mutation of the PALLD gene (NM_001166108.1:c.G154A:p.D52N) was detected in the index patient with pancreatic cancer and the tumor tissue of her sister. Whole genome sequencing showed similar somatic mutation patterns between the 2 sisters. Apart from the PALLD mutation, commonly mutated genes that characterize pancreatic ductal adenocarcinoma were found in both tumor samples. However, the 2 patients harbored different somatic KRAS mutations (G12D and G12V). Healthy siblings did not have the PALLD mutation, indicating a disease-specific impact. Compartment-specific gene expression data and IHC showed expression in cancer-associated fibroblasts (CAFs).CONCLUSIONWe identified a germline mutation of the palladin (PALLD) gene in 2 siblings in Europe, affected by familial pancreatic cancer, with a significant overexpression in CAFs, suggesting that stromal palladin could play a role in the development, maintenance, and/or progression of pancreatic cancer.FUNDINGDFG SFB 1321.
Collapse
Affiliation(s)
- Lucia Liotta
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Sebastian Lange
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - H. Carlo Maurer
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
- Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA
| | - Kenneth P. Olive
- Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA
| | - Rickmer Braren
- Institut für diagnostische und interventionelle Radiologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Nicole Pfarr
- Institut für Pathologie und pathologische Anatomie, Technische Universität München, Munich, Germany
| | - Sebastian Burger
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Alexander Muckenhuber
- Institut für Pathologie und pathologische Anatomie, Technische Universität München, Munich, Germany
| | - Moritz Jesinghaus
- Institut für Pathologie und pathologische Anatomie, Technische Universität München, Munich, Germany
| | - Katja Steiger
- Institut für Pathologie und pathologische Anatomie, Technische Universität München, Munich, Germany
| | - Wilko Weichert
- Institut für Pathologie und pathologische Anatomie, Technische Universität München, Munich, Germany
- Deutschen Konsortium für Translationale Krebsforschung (DKTK), Partner site Munich, Technische Universität München, Munich, Germany
| | - Helmut Friess
- Chirurgische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Roland Schmid
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Hana Algül
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Philipp J. Jost
- Deutschen Konsortium für Translationale Krebsforschung (DKTK), Partner site Munich, Technische Universität München, Munich, Germany
- Innere Medizin III, Hämatologie und Onkologie, Technische Universität München, Munich, Germany
| | - Juliane Ramser
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Christine Fischer
- Institut für Humangenetik, Ruprecht-Karls Universität, Heidelberg, Germany
| | - Anne S. Quante
- Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Maximilian Reichert
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
- Deutschen Konsortium für Translationale Krebsforschung (DKTK), Partner site Munich, Technische Universität München, Munich, Germany
| | - Michael Quante
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
- Deutschen Konsortium für Translationale Krebsforschung (DKTK), Partner site Munich, Technische Universität München, Munich, Germany
- Klinik für Innere Medizin II, Universität Freiburg, Germany
| |
Collapse
|
3
|
Dantes Z, Yen HY, Pfarr N, Winter C, Steiger K, Muckenhuber A, Hennig A, Lange S, Engleitner T, Öllinger R, Maresch R, Orben F, Heid I, Kaissis G, Shi K, Topping G, Stögbauer F, Wirth M, Peschke K, Papargyriou A, Rezaee-Oghazi M, Feldmann K, Schäfer AP, Ranjan R, Lubeseder-Martellato C, Stange DE, Welsch T, Martignoni M, Ceyhan GO, Friess H, Herner A, Liotta L, Treiber M, von Figura G, Abdelhafez M, Klare P, Schlag C, Algül H, Siveke J, Braren R, Weirich G, Weichert W, Saur D, Rad R, Schmid RM, Schneider G, Reichert M. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight 2020; 5:137809. [PMID: 32614802 DOI: 10.1172/jci.insight.137809] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Accepted: 06/24/2020] [Indexed: 01/05/2023] Open
Abstract
One of the major challenges in using pancreatic cancer patient-derived organoids (PDOs) in precision oncology is the time from biopsy to functional characterization. This is particularly true for endoscopic ultrasound-guided fine-needle aspiration biopsies, typically resulting in specimens with limited tumor cell yield. Here, we tested conditioned media of individual PDOs for cell-free DNA to detect driver mutations already early on during the expansion process to accelerate the genetic characterization of PDOs as well as subsequent functional testing. Importantly, genetic alterations detected in the PDO supernatant, collected as early as 72 hours after biopsy, recapitulate the mutational profile of the primary tumor, indicating suitability of this approach to subject PDOs to drug testing in a reduced time frame. In addition, we demonstrated that this workflow was practicable, even in patients for whom the amount of tumor material was not sufficient for molecular characterization by established means. Together, our findings demonstrate that generating PDOs from very limited biopsy material permits molecular profiling and drug testing. With our approach, this can be achieved in a rapid and feasible fashion with broad implications in clinical practice.
Collapse
Affiliation(s)
- Zahra Dantes
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Hsi-Yu Yen
- Institute of Pathology.,Comparative Experimental Pathology, and
| | | | - Christof Winter
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, Germany.,German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Katja Steiger
- Institute of Pathology.,Comparative Experimental Pathology, and
| | | | - Alexander Hennig
- Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technical University of Dresden, Dresden, Germany
| | - Sebastian Lange
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Thomas Engleitner
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Rupert Öllinger
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Roman Maresch
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Felix Orben
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | | | | | - Kuangyu Shi
- Department of Nuclear Medicine, Technical University of Munich, Munich, Germany
| | - Geoffrey Topping
- Department of Nuclear Medicine, Technical University of Munich, Munich, Germany
| | | | - Matthias Wirth
- Medical Department, Division of Hematology and Oncology at Campus Benjamin Franklin, Charité, Berlin, Germany
| | - Katja Peschke
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | | | | | - Karin Feldmann
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Arlett Pg Schäfer
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Raphela Ranjan
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | | | - Daniel E Stange
- German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technical University of Dresden, Dresden, Germany.,DKTK, partner site Dresden, Germany
| | - Thilo Welsch
- German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technical University of Dresden, Dresden, Germany.,DKTK, partner site Dresden, Germany
| | - Marc Martignoni
- Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - Güralp O Ceyhan
- Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - Helmut Friess
- Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - Alexander Herner
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Lucia Liotta
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Matthias Treiber
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Guido von Figura
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | | | - Peter Klare
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Christoph Schlag
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Hana Algül
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Jens Siveke
- German Cancer Research Center (DKFZ), Heidelberg, Germany.,Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen, Essen, Germany.,Division of Solid Tumor Translational Oncology, DKTK, partner site Essen, Germany
| | - Rickmer Braren
- German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technical University of Dresden, Dresden, Germany
| | | | - Wilko Weichert
- Institute of Pathology.,German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dieter Saur
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar.,German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Roland Rad
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar.,German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Roland M Schmid
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar
| | - Günter Schneider
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar.,German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Maximilian Reichert
- Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar.,German Cancer Consortium (DKTK), partner site Munich, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
4
|
Liotta L, Quante M. [Adjuvant chemotherapy with Capecitabine as new standard for resected cholangiocarcinomas - a look at the BILCAP trial]. Z Gastroenterol 2018; 56:839-840. [PMID: 29986358 DOI: 10.1055/s-0044-100936] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
5
|
Pierobon M, Wong S, Reeded A, Anthony S, Robert N, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Carpten J, Petricoin EF. Abstract P1-07-09: A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-07-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: While genomic alterations are central players in tumor progression, proteins are the targets for precision therapy. The degree by which “actionable” genomic alterations translate into activated/altered proteins and pathway is still under investigation. Using a multi-OMIC approach from the SideOut 2 metastatic breast cancer (MBC) trial, this study explored the concordance between selected “actionable” genomic alterations and protein expression/activation.
Methods: Snap frozen biopsies from 29 MBC patients enrolled in a prospective phase II trial were used for this analysis. Exome WES and RNASeq data was processed using an in-house developed pipeline and identified amplification of CCND1 (6/29), FGFR1 (4/29), and FGF 3, 4, 5, and 19 (4/29) as some of most frequent “actionable” genomic alterations in our MBC cohort. Signaling analysis of the 29 cases was performed using Reverse Phase Protein Microarray coupled with Laser Capture Microdissection. Protein expression/phosphorylation was measured in a continuous scale and classified based on quartile distribution. Concordance between CCND1 amplification and Cyclin D1 expression, along with the activation of FOXM1 T600 and Rb S780, was explored. Amplification of the FGFR1 locus or its ligands was correlated with the level of activation/phosphorylation of FGFR1 Y653/654.
Results: While Cyclin D1 protein expression was greater than the population mean for 4/6 (67%) patients with CCND1 amplification, only 2/6 (33%) patients with CCND1 amplification had Cyclin D1 level within the top quartile of the population (n=29). FOXM1 T600 activation was independent from CCND1 amplification, with high levels of FOXM1 T600 predominantly in the CCND1 wild-type population. Only 1/6 (17%) patients with CCND1 amplification had FOXM1 T600 level similar to the top quartile of the population while a second patient was above the population median. Activation of Rb S780 was above the population median, but below the top quartile, in 2/6 (33%) CCND1 amplified patients. Similarly, none of the patients with activation of FGFR Y653/654 equal to the top quartile harbored an FGFR1 amplification. Only 1/4 (25%) patients carrying an FGFR1 amplification had an activation of FGFR Y653/654 above the population median. Similarly, 1/4 (25%) patients with FGF ligand amplification showed FGFR Y653/654 level within the top quartile while three patients had FGFR Y653/654 activation below the population median. No significant results were found between proteomic (below/above the median) and genomic characteristics by Fisher test (p>0.05).
Conclusion: Molecular genotyping of “actionable” cancer targets alone may be insufficient in predicting whether the actual drug target protein is expressed and/or activated in any given patient's tumor. Although these results need further validation, the combination of genomic and proteomic data may represent a more informative approach for identifying real molecular drivers of individual lesions as well as “actionable” protein/phosphoprotein targets in the absence of genomic events. Multi-OMIC approaches may lead to more effective stratification in precision medicine trials.
Citation Format: Pierobon M, Wong S, Reeded A, Anthony S, Robert N, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Carpten J, Petricoin EF. A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-07-09.
Collapse
Affiliation(s)
- M Pierobon
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - S Wong
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - A Reeded
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - S Anthony
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - N Robert
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - DW Northfelt
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - M Jahanzeb
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - L Vocila
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - J Wulfkuhle
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - B Dunetz
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - J Aldrich
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - S Byron
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - D Craig
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - L Liotta
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - J Carpten
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| | - EF Petricoin
- George Mason University, Manassas, VA; Translational Genomics Research Institut, Pheonix, AZ; Virginia Cancer Specialists/US Oncology, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; The Side Out Foundation, Fairfax, VA; Keck School of Medicine, Los Angeles, CA; Arizona Oncology, Sedona, AZ
| |
Collapse
|
6
|
Liotta L, Madonia G, Chiofalo B, Margiotta S, Riolo EB, Chiofalo V. Milk composition of “Nero Siciliano” sow. Preliminary results. Italian Journal of Animal Science 2016. [DOI: 10.4081/ijas.2007.1s.692] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- L. Liotta
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
| | - G. Madonia
- Istituto Sperimentale Zootecnico per la Sicilia. Palermo, Italy
| | - B. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
| | - S. Margiotta
- Istituto Sperimentale Zootecnico per la Sicilia. Palermo, Italy
| | - E. B. Riolo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
| | - V. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
| |
Collapse
|
7
|
Pellecchia M, Colli L, Bigi D, Zambonelli P, Supplizi V, Liotta L, Negrini R, Marsan A. Mitochondrial DNA diversity of five Italian autochtonous donkey breeds. Italian Journal of Animal Science 2016. [DOI: 10.4081/ijas.2007.1s.185] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- M. Pellecchia
- Istituto di Zootecnica. Università Cattolica del Sacro Cuore, Piacenza, Italy
| | - L. Colli
- Istituto di Zootecnica. Università Cattolica del Sacro Cuore, Piacenza, Italy
| | - D. Bigi
- Dipartimento di Produzione e valorizzazione Agroalimentare, Università di Bologna, Italy
| | - P. Zambonelli
- Dipartimento di Produzione e valorizzazione Agroalimentare, Università di Bologna, Italy
| | - Verini Supplizi
- Dipartimento di Patologia, Diagnostica e Clinica Veterinaria, Università di Perugia, Italy
| | - L. Liotta
- Dipartimento di Morfologia Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - R. Negrini
- Istituto di Zootecnica. Università Cattolica del Sacro Cuore, Piacenza, Italy
| | - Ajmone Marsan
- Istituto di Zootecnica. Università Cattolica del Sacro Cuore, Piacenza, Italy
| |
Collapse
|
8
|
Liotta L, Chiofalo B, Zumbo A, Chiofalo V. Effects of different nutritional levels on Nero Siciliano pig performance. Italian Journal of Animal Science 2016. [DOI: 10.4081/ijas.2005.2s.470] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
9
|
Pierobon M, Wong S, Reeder A, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Petricoin EF, Carpten J. Abstract P2-05-21: The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-05-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The identification of organ-specific targetable signatures may help design more effective treatment for patients with metastatic breast cancer (MBC). We took a multi-OMIC approach to assess whether the AKT-mTOR pathway is globally activated during metastatic progression or whether it represents an organ-specific target.
Methods: Snap frozen biopsies from 25 MBC patients enrolled in a prospective phase II trial were used. Sites of metastasis were classified as liver (n=8) and others (n=17), the latter including cutaneous, lung, lymph nodes, and intra-abdominal lesions. Signaling analysis of the 25 cases was performed using Reverse Phase Protein Microarray (RPPA) coupled with Laser Capture Microdissection. Activation of the AKT-mTOR pathway was quantified as phosphorylation of AKT (S473) and the mTOR target p70S6 (T389). Matched exome (WES) and RNASeq data were available for 17 of 25 patients, five with liver metastases. Sequencing data was processed using an in-house developed pipeline to identify somatic events including coding mutations, copy number alterations, gene fusions, and differential expression. Activation of the AKT-mTOR pathway and sequencing data were compared between hepatic and non-hepatic lesions using an integrated RPPA and genomic approach.
Results: Among liver metastases, AKT was activated in 4 of the 8 (50.0%) patients, while 6 of the 8 cases (75.0%) showed activation of p70S6. Sequencing data revealed mutation of PIK3CA in 4 of the 5 liver metastases (80.0%). Three of the PIK3CA mutated specimens with catalytic domain mutations (codons 1023 and 147) demonstrated co-activation of AKT and p70S6, while the fourth case, containing a helical domain mutation (E542K), had activation of p70S6 only. The PIK3CA wild-type liver metastasis demonstrated low activation of AKT and p70S6. For non-hepatic metastases AKT was activated in 2 of the 17 cases (11.8%) and p70S6 in 5 of the 17 patients (29.4%).
Discussion: Although these results need further validation, activation of the AKT-mTOR pathway appears to be a hepatic specific signature in MBC and could be used for the selection of targeted agents for hepatic lesions.
Citation Format: Pierobon M, Wong S, Reeder A, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Petricoin EF, Carpten J. The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-21.
Collapse
Affiliation(s)
- M Pierobon
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - S Wong
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - A Reeder
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - SP Anthony
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - NJ Robert
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - DW Northfelt
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - M Jahanzeb
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - L Vocila
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - J Wulfkuhle
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - B Dunetz
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - J Aldrich
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - S Byron
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - D Craig
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - L Liotta
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - EF Petricoin
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| | - J Carpten
- George Mason University, Manassas, VA; Translational Genomics Research Institute, Phoenix, AZ; Evergreen Hematology & On, Spokane, WA; Virginia Cancer Specialists, Fairfax, VA; Mayo Clinic Arizona, Scottsdale, AZ; University of Miami Sylvester Comprehensive Cancer Center, Deerfield Campus, Deerfield Beach, FL; TD2 Translational Drug Development, Scottsdale, AZ; Side Out Foundation, Fairfax, VA
| |
Collapse
|
10
|
Pini Prato A, Carlucci M, Bagolan P, Gamba PG, Bernardi M, Leva E, Paradies G, Manzoni C, Noccioli B, Tramontano A, Jasonni V, Vaccarella F, De Pascale S, Alberti D, Riccipetitoni G, Falchetti D, Caccia F, Pelizzo G, Schleef J, Lima M, Andriolo P, Franchella A, Cacciari A, Caravaggi F, Federici S, Andermarcher M, Perrino G, Codrich D, Camoglio FS, Chiarenza FS, Martino A, Appignani A, Briganti V, Caterino S, Cozzi D, Messina M, Rizzo A, Liotta L, Salerno D, Aceti MGR, Bartoli F, Romeo C, Esposito C, Lelli Chiesa PL, Clemente E, Mascia L, Cacciaguerra S, Di Benedetto V, Licciardi S, De Grazia E, Ubertazzi M, Piazza G, Mattioli G, Rossi F, Nobili M. A cross-sectional nationwide survey on esophageal atresia and tracheoesophageal fistula. J Pediatr Surg 2015; 50:1441-56. [PMID: 25783403 DOI: 10.1016/j.jpedsurg.2015.01.004] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Revised: 01/07/2015] [Accepted: 01/09/2015] [Indexed: 01/29/2023]
Abstract
BACKGROUND Our study aims at disclosing epidemiology and most relevant clinical features of esophageal atresia (EA) pointing to a model of multicentre collaboration. METHODS A detailed questionnaire was sent to all Italian Units of pediatric surgery in order to collect data of patients born with EA between January and December 2012. The results were crosschecked by matching date and place of birth of the patients with those of diagnosis-related group provided by the Italian Ministry of Health (MOH). RESULTS A total of 146 questionnaires were returned plus a further 32 patients reported in the MOH database. Basing on a total of 178 patients with EA born in Italy in 2012, the incidence of EA was calculated in 3.33 per 10,000 live births. Antenatal diagnosis was suspected in 29.5% patients. 55.5% showed associated anomalies. The most common type of EA was Gross type C (89%). Postoperative complications occurred in 37% of type C EA and 100% of type A EA. A 9.5% mortality rate was reported. CONCLUSIONS This is the first Italian cross-sectional nationwide survey on EA. We can now develop shared guidelines and provide more reliable prognostic expectations for our patients.
Collapse
Affiliation(s)
| | - M Carlucci
- Istituto Giannina Gaslini, Genova, Italy
| | - P Bagolan
- Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - P G Gamba
- Azienda Ospedaliero-Universitaria, Padova, Italy
| | - M Bernardi
- Azienda Ospedaliera della Provincia di Lecco, Merate, Italy
| | - E Leva
- Ospedale Maggiore Policlinico Magiagalli, Milano, Italy
| | | | | | - B Noccioli
- Ospedale Pediatrico Meyer, Firenze, Italy
| | - A Tramontano
- Azienda Ospedaliera Pediatrica Santobono Pausilipon, Napoli, Italy
| | - V Jasonni
- Istituto Giannina Gaslini, Genova, Italy; Università degli Studi di Genova, Genova, Italy
| | - F Vaccarella
- ASN SS: Antonio e Biagio e Cesare Arrigo, Alessandria
| | | | | | | | | | - F Caccia
- Ospedale San Carlo Borromeo, Milano
| | | | - J Schleef
- Ospedale Infantile Regina Margherita, Torino
| | - M Lima
- Ospedale Sant'Orsola Malpighi, Bologna
| | | | | | | | | | | | | | | | - D Codrich
- Ospedale Infantile Burlo Garofalo, Trieste
| | | | | | | | - A Appignani
- Ospedale Santa Maria della Misericordia, Perugia
| | | | | | | | - M Messina
- Ospedale Policlinico Santa Maria alle Scotte, Siena
| | | | - L Liotta
- Ospedale Francesco Ferrari, Casarano
| | - D Salerno
- Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro
| | | | - F Bartoli
- Azienda Ospedaliera Universitaria-Ospedali Riuniti, Foggia
| | - C Romeo
- Azienda Ospedaliero-Universitaria G. Martino, Messina
| | - C Esposito
- Policlinico Universitario Federico II, Napoli
| | | | - E Clemente
- Azienda Ospedaliera Universitaria S. Giovanni di Dio e Ruggi d'Aragona, Salerno
| | | | | | | | | | - E De Grazia
- Azienda Ospedaliero-Universitaria Policlinico P. Giaccone
| | | | - G Piazza
- Ospedale Sant'Antonio Abate, Trapani
| | | | - F Rossi
- Ospedale Maggiore della carità, Novara
| | - M Nobili
- Azienda Ospedaliera Universitaria-Ospedali Riuniti, Foggia
| |
Collapse
|
11
|
Liotta L, Arcudi D, Panetta C, Siclari A, D'Alessandro E. Uso dell'analisi d'immagine per la caratterizzazione fenotipica della popolazione asinina calabrese. Arch zootec 2014. [DOI: 10.4321/s0004-05922014000300016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
12
|
Geller T, Prakash V, Batanian J, Guzman M, Duncavage E, Gershon T, Crowther A, Wu J, Liu H, Fang F, Davis I, Tripolitsioti D, Ma M, Kumar K, Grahlert J, Egli K, Fiaschetti G, Shalaby T, Grotzer M, Baumgartner M, Braoudaki M, Lambrou GI, Giannikou K, Millionis V, Papadodima SA, Settas N, Sfakianos G, Stefanaki K, Kattamis A, Spiliopoulou CA, Tzortzatou-Stathopoulou F, Kanavakis E, Gholamin S, Mitra S, Feroze A, Zhang M, Esparza R, Kahn S, Richard C, Achrol A, Volkmer A, Liu J, Volkmer J, Majeti R, Weissman I, Cheshier S, Bhatia K, Brown N, Teague J, Lo P, Challis J, Beshay V, Sullivan M, Mechinaud F, Hansford J, Arifin MZ, Dahlan RH, Sobana M, Saputra P, Tisell MT, Danielsson A, Caren H, Bhardwaj R, Chakravadhanula M, Hampton C, Ozals V, Georges J, Decker W, Kodibagkar V, Nguyen A, Legrain M, Gaub MP, Pencreach E, Chenard MP, Guenot D, Entz-Werle N, Kanemura Y, Ichimura K, Shofuda T, Nishikawa R, Yamasaki M, Shibui S, Arai H, Xia J, Brian A, Prins R, Pennell C, Moertel C, Olin M, Bie L, Zhang X, Liu H, Olsson M, Kling T, Nelander S, Biassoni V, Bongarzone I, Verderio P, Massimino M, Magni R, Pizzamiglio S, Ciniselli C, Taverna E, De Bortoli M, Luchini A, Liotta L, Barzano E, Spreafico F, Visse E, Sanden E, Darabi A, Siesjo P, Jackson S, Cohen K, Lin D, Burger P, Rodriguez F, Yao X, Liucheng R, Qin L, Na T, Meilin W, Zhengdong Z, Yongjun F, Pfeifer S, Nister M, de Stahl TD, Basmaci E, Orphanidou-Vlachou E, Brundler MA, Sun Y, Davies N, Wilson M, Pan X, Arvanitis T, Grundy R, Peet A, Eden C, Ju B, Phoenix T, Nimmervoll B, Tong Y, Ellison D, Lessman C, Taylor M, Gilbertson R, Folgiero V, del Bufalo F, Carai A, Cefalo MG, Citti A, Rutella S, Locatelli F, Mastronuzzi A, Maher O, Khatua S, Zaky W, Lourdusamy A, Meijer L, Layfield R, Grundy R, Jones DTW, Capper D, Sill M, Hovestadt V, Schweizer L, Lichter P, Zagzag D, Karajannis MA, Aldape KD, Korshunov A, von Deimling A, Pfister S, Chakrabarty A, Feltbower R, Sheridon E, Hassan H, Shires M, Picton S, Hatziagapiou K, Braoudaki M, Lambrou GI, Tsorteki F, Tzortzatou-Stathopoulou F, Bethanis K, Gemou-Engesaeth V, Chi SN, Bandopadhayay P, Janeway K, Pinches N, Malkin H, Kieran MW, Manley PE, Green A, Goumnerova L, Ramkissoon S, Harris MH, Ligon KL, Kahlert U, Suarez M, Maciaczyk J, Bar E, Eberhart C, Kenchappa R, Krishnan N, Forsyth P, McKenzie B, Pisklakova A, McFadden G, Kenchappa R, Forsyth P, Pan W, Rodriguez L, Glod J, Levy JM, Thompson J, Griesinger A, Amani V, Donson A, Birks D, Morgan M, Handler M, Foreman N, Thorburn A, Lulla RR, Laskowski J, Fangusaro J, DiPatri AJ, Alden T, Tomita T, Vanin EF, Goldman S, Soares MB, Remke M, Ramaswamy V, Wang X, Jorgensen F, Morrissy AS, Marra M, Packer R, Bouffet E, Pfister S, Jabado N, Taylor M, Cole B, Rudzinski E, Anderson M, Bloom K, Lee A, Leary S, Leprivier G, Remke M, Rotblat B, Agnihotri S, Kool M, Derry B, Pfister S, Taylor MD, Sorensen PH, Dobson T, Busschers E, Taylor H, Hatcher R, Fangusaro J, Lulla R, Goldman S, Rajaram V, Das C, Gopalakrishnan V. TUMOUR BIOLOGY. Neuro Oncol 2014; 16:i137-i145. [PMCID: PMC4046298 DOI: 10.1093/neuonc/nou082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/22/2023] Open
|
13
|
Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res 2014; 13:2846-55. [PMID: 24787230 DOI: 10.1021/pr401267m] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
This nonrandomized phase I/II trial assessed the efficacy/tolerability of imatinib plus panitumumab in patients affected by metastatic colorectal cancer (mCRC) after stratification to treatment by selection of activated imatinib drug targets using reverse-phase protein array (RPPA). mCRC patients presenting with a biopsiable liver metastasis were enrolled. Allocation to the experimental and control arms was established using functional pathway activation mapping of c-Kit, PDGFR, and c-Abl phosphorylation by RPPA. The experimental arm received run-in escalation therapy with imatinib followed by panitumumab. The control arm received panitumumab alone. Seven patients were enrolled in the study. For three of the seven patients, sequential pre- and post-treatment biopsies were used to evaluate the effect of the therapeutic compounds on the drug targets and substrates. A decrease in the activation level of the drug targets and downstream substrates was observed in two of three patients. Combination therapy increased the activation of the AKT-mTOR pathway and several receptor tyrosine kinases. This study proposes a novel methodology for stratifying patients to personalized treatment based on the activation level of the drug targets. This workflow provides the ability to monitor changes in the signaling pathways after the administration of targeted therapies and to identify compensatory mechanisms.
Collapse
Affiliation(s)
- M Pierobon
- Center for Applied Proteomics and Molecular Medicine, George Mason University , 10900 University Boulevard, Manassas, Virginia 20110, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Liotta L, Arcudi D, Panetta C, Siclari A, D'Alessandro E. Uso dell'analisi d'immagine per la caratterizzazione fenotipica della popolazione asinina Calabrese. ARCH ZOOTEC 2014. [DOI: 10.21071/az.v63i243.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Lo studio ha riguardato la caratterizzazione fenotipica di 56 soggetti (tra 2 e 30 anni di età) riconducibili alla popolazione asinina Calabrese, allevati in 23 aziende. Su ciascun soggetto sono stati eseguiti i più significativi rilievi morfometrici mediante l’impiego di un sistema di analisi d’immagine computerizzato. Tali dati sono stati successi-vamente utilizzati per il calcolo dei più significativi indici biometrici. Inoltre sono stati presi in considerazione il colore e le eventuali particolarità del mantello. Gli indici biometrici ricavati ci hanno permesso di inquadrare questa popolazione asinina nel tipo dolicomorfo, come evidenziato dai valori dell’Indice di conformazione laterale del corpo (97,78), dell’Indice toracico di profilo (44,85), dell’Indice di Compattezza (90,80), dell’Indice lunghezza torace (100,79) e dell’Indice di ossatura (12,82). Il colore del mantello è risultato essere principalmente morello (75 %) anche se si è osser-vata la presenza di soggetti baio scuro (20 %) e grigio (5 %). Il colore dell’addome costantemente bianco come anche il muso e le occhiaie. Il colore dell’ano, vulva e mammella è costantemente nero.
Collapse
|
15
|
Macrì F, Ciotola F, Rapisarda G, Lanteri G, Albarella S, Aiudi G, Liotta L, Marino F. A rare case of simple syndactyly in a puppy. J Small Anim Pract 2013; 55:170-3. [DOI: 10.1111/jsap.12165] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- F. Macrì
- Department of Veterinary Science - University of Messina; Polo Universitario dell'Annunziata; 98168 Messina Italy
| | - F. Ciotola
- Department of Health Sciences; University Magna Graecia of Catanzaro; Catanzaro Italy
| | - G. Rapisarda
- Asp Siracusa n° 8 Distretto di Noto; Via Montessori 96017 Siracusa Italy
| | - G. Lanteri
- Department of Veterinary Science - University of Messina; Polo Universitario dell'Annunziata; 98168 Messina Italy
| | - S. Albarella
- Department of Veterinary Medicine and Animal Productions; University of Naples Federico II; Naples Italy
| | - G. Aiudi
- Department of Animal Production; Faculty of Veterinary Medicine; Bari Italy
| | - L. Liotta
- Department of Veterinary Science - University of Messina; Polo Universitario dell'Annunziata; 98168 Messina Italy
| | - F. Marino
- Department of Veterinary Science - University of Messina; Polo Universitario dell'Annunziata; 98168 Messina Italy
| |
Collapse
|
16
|
Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B, Boe A, DaFonseca S, Chomont N, Liotta L, Petricoin EI, Norelli S, Pelosi E, Garaci E, Savarino A, Palamara AT. A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis 2013; 4:e944. [PMID: 24309931 PMCID: PMC3877546 DOI: 10.1038/cddis.2013.473] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Revised: 10/26/2013] [Accepted: 10/31/2013] [Indexed: 01/05/2023]
Abstract
Central memory (TCM) and transitional memory (TTM) CD4+ T cells are known to be the major cellular reservoirs for HIV, as these cells can harbor a transcriptionally silent form of viral DNA that is not targeted by either the immune system or current antiretroviral drug regimens. In the present study, we explored the molecular bases of the anti-HIV reservoir effects of auranofin (AF), a pro-oxidant gold-based drug and a candidate compound for a cure of AIDS. We here show that TCM and TTM lymphocytes have lower baseline antioxidant defenses as compared with their naive counterpart. These differences are mirrored by the effects exerted by AF on T-lymphocytes: AF was able to exert a pro-differentiating and pro-apoptotic effect, which was more pronounced in the memory subsets. AF induced an early activation of the p38 mitogen-activated protein kinase (p38 MAPK) followed by mitochondrial depolarization and a final burst in intracellular peroxides. The pro-differentiating effect was characterized by a downregulation of the CD27 marker expression. Interestingly, AF-induced apoptosis was inhibited by pyruvate, a well-known peroxide scavenger, but pyruvate did not inhibit the pro-differentiating effect of AF, indicating that the pro-apoptotic and pro-differentiating effects involve different pathways. In conclusion, our results demonstrate that AF selectively targets the TCM/TTM lymphocyte subsets, which encompass the HIV reservoir, by affecting redox-sensitive cell death pathways.
Collapse
Affiliation(s)
- B Chirullo
- Istituto Superiore di Sanità, Viale Regina Elena, 299, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Macrì F, Liotta L, Bonfiglio R, De Stefano C, Ruscica D, Aiudi G. Ultrasound measurement of reproductive organs in juvenile European sea bass Dicentrarchus labrax. J Fish Biol 2013; 83:1439-1443. [PMID: 24117993 DOI: 10.1111/jfb.12228] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 08/13/2013] [Indexed: 06/02/2023]
Abstract
In this study, ultrasonographic examination was performed thrice, 15 days apart, on juvenile European sea bass Dicentrarchus labrax, from 330 to 360 days of age, to assess the size and the morphology of male and female. Results have proved this method as a suitable and non-invasive procedure to assess sexual differentiation.
Collapse
Affiliation(s)
- F Macrì
- Department of Veterinary Sciences, University of Messina, Polo Universitario dell'Annunziata, 98168 Messina, Italy
| | | | | | | | | | | |
Collapse
|
18
|
Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. J Intern Med 2013; 274:1-24. [PMID: 23527888 DOI: 10.1111/joim.12070] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.
Collapse
Affiliation(s)
- A Silvestri
- Division of Experimental Oncology 2, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Colli L, Perrotta G, Negrini R, Bomba L, Bigi D, Zambonelli P, Verini Supplizi A, Liotta L, Ajmone-Marsan P. Detecting population structure and recent demographic history in endangered livestock breeds: the case of the Italian autochthonous donkeys. Anim Genet 2012; 44:69-78. [DOI: 10.1111/j.1365-2052.2012.02356.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2012] [Indexed: 11/29/2022]
Affiliation(s)
- L. Colli
- Istituto di Zootecnica e BioDNA Centro di Ricerca sulla Biodiversità e il DNA Antico; Facoltà di Agraria; Università Cattolica del S. Cuore di Piacenza; I-29122; Piacenza; Italy
| | - G. Perrotta
- Laboratorio di Genetica e Servizi L.G.S.; I-26100; Cremona; Italy
| | - R. Negrini
- Istituto di Zootecnica e BioDNA Centro di Ricerca sulla Biodiversità e il DNA Antico; Facoltà di Agraria; Università Cattolica del S. Cuore di Piacenza; I-29122; Piacenza; Italy
| | - L. Bomba
- Istituto di Zootecnica e BioDNA Centro di Ricerca sulla Biodiversità e il DNA Antico; Facoltà di Agraria; Università Cattolica del S. Cuore di Piacenza; I-29122; Piacenza; Italy
| | - D. Bigi
- Dipartimento di Protezione e Valorizzazione Agro-Alimentare; Università di Bologna - Sede di Reggio Emilia; I-42123; Reggio Emilia; Italy
| | - P. Zambonelli
- Dipartimento di Protezione e Valorizzazione Agro-Alimentare; Università di Bologna - Sede di Reggio Emilia; I-42123; Reggio Emilia; Italy
| | - A. Verini Supplizi
- Dipartimento di Patologia; Diagnostica e Clinica Veterinaria; Università di Perugia; I-06126; Perugia; Italy
| | - L. Liotta
- Dipartimento di Morfologia, Biochimica; Fisiologia e Produzioni Animali; Università di Messina; I-98168; Messina; Italy
| | - P. Ajmone-Marsan
- Istituto di Zootecnica e BioDNA Centro di Ricerca sulla Biodiversità e il DNA Antico; Facoltà di Agraria; Università Cattolica del S. Cuore di Piacenza; I-29122; Piacenza; Italy
| |
Collapse
|
20
|
Napoletani D, Signore M, Sauer T, Liotta L, Petricoin E. Homologous control of protein signaling networks. J Theor Biol 2011; 279:29-43. [DOI: 10.1016/j.jtbi.2011.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2009] [Revised: 03/06/2011] [Accepted: 03/17/2011] [Indexed: 11/26/2022]
|
21
|
Romano A, Palumbo G, Giallongo C, La Cava P, Branca A, Tibullo D, Vetro C, Amico I, Di Raimondo F, Liotta L, Espina V. 129 5-Azacytidine activates autophagy independently from disease status and the quality of achieved response. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70131-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Ross MM, Zhang H, Tian Y, Kulasingam V, Drabovich AP, Smith C, Batruch I, Liotta L, Petricoin E, Diamandis EP, Chan DW, Lopez MF. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res 2010; 9:6678-88. [PMID: 20945832 DOI: 10.1021/pr100821m] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Mass spectrometry (MS) is an attractive alternative to quantification of proteins by immunoassays, particularly for protein biomarkers of clinical relevance. Reliable quantification requires that the MS-based assays are robust, selective, and reproducible. Thus, the development of standardized protocols is essential to introduce MS into clinical research laboratories. The aim of this study was to establish a complete workflow for assessing the transferability and reproducibility of selected reaction monitoring (SRM) assays between clinical research laboratories. Four independent laboratories in North America, using identical triple-quadrupole mass spectrometers (Quantum Ultra, Thermo), were provided with standard protocols and instrumentation settings to analyze unknown samples and internal standards in a digested plasma matrix to quantify 51 peptides from 39 human proteins using a multiplexed SRM assay. The interlaboratory coefficient of variation (CV) was less than 10% for 25 of 39 peptides quantified (12 peptides were not quantified based upon hydrophobicity) and exhibited CVs less than 20% for the remaining peptides. In this report, we demonstrate that previously developed research platforms for SRM assays can be improved and optimized for deployment in clinical research environments.
Collapse
Affiliation(s)
- A Prakash
- Thermo Fisher Scientific, Biomarker research in Mass Spectrometry, Cambridge, Massachusettes, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Fontanesi L, D’Alessandro E, Scotti E, Liotta L, Crovetti A, Chiofalo V, Russo V. Genetic heterogeneity and selection signature at the KIT gene in pigs showing different coat colours and patterns. Anim Genet 2010; 41:478-92. [DOI: 10.1111/j.1365-2052.2010.02054.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
24
|
Di Meo G, Perucatti A, Peretti V, Incarnato D, Ciotola F, Liotta L, Raudsepp T, Di Berardino D, Chowdhary B, Iannuzzi L. The 450-Band Resolution G- and R-Banded Standard Karyotype of the Donkey ( Equus asinus, 2n = 62). Cytogenet Genome Res 2009; 125:266-71. [DOI: 10.1159/000235932] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/14/2009] [Indexed: 11/19/2022] Open
|
25
|
Liotta L, Pierobon M, Wulfkuhle J, Laird J, Livasy C, Espina V, Esserman L, Petricoin E. Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11014 Background: ER and HER2 measurements underpin a majority of breast cancer clinical testing, yet determination of ER and HER2 protein levels are routinely performed using subjective approaches. We have developed a semi-quantitative calibrated protein microarray, the Reverse Phase Protein Microarray (RPMA), to more adequately determine accurate and precise protein expression levels in clinical tissue specimens. We utilized this method to determine HER2 and ER expression levels and compared the results to those values reported from the clinical laboratory. Methods: Pure tumor epithelium from 149 frozen pre-treatment human breast cancer tissue specimens (from the I-SPY TRIAL: CALGB 150007/150012, ACRIN 6657) were procured via Laser Capture Microdissection and protein pathway mapping was performed whereby the ER (N=112) and HER2 (N= 118) levels were directly measured and compared with reported IHC values. Results: Overall, RPMA measurements of HER2 had excellent correlation with IHC and FISH HER2 determination with no IHC or FISH false positives (88/88). 7 out of 30 of the FISH/IHC+ cases were found by RPMA to have HER2 values as low or lower than the FISH/IHC- cases with the HER2+ population having RPMA expression levels that varied by as much as 10-fold. There was less concordance between RPMA ER values and IHC ER values. Detailed analysis of a more homogeneous ER+ population (Allred =8) revealed a large dynamic range of expression of ER (10–20 fold) by RPMA. The HER2 and ER RPMA results were independently validated by Western Blot using a separate biopsy. Conclusions: Discreet protein expression values obtained by RPMA for ER and HER2 reveal distinctly broad expression values, with as much as 10–20 fold dynamic range in expression, even in a homogeneous (e.g. Allred score of 8) population. Such dynamic differences in protein expression may produce dramatic effects in therapeutic response rate. These findings, if found to be clinically useful, point to a potential need for more fine-tuned protein expression determination by quantitative high-throughput technologies for patient stratification even for standard-of-care FDA approved therapies. [Table: see text]
Collapse
Affiliation(s)
- L. Liotta
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - M. Pierobon
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - J. Wulfkuhle
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - J. Laird
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - C. Livasy
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - V. Espina
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - L. Esserman
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| | - E. Petricoin
- I-SPY Investigators; George Mason University, Manassas, VA; University of California, San Francisco, CA; University of North Carolina, Chapel Hill, NC
| |
Collapse
|
26
|
Khalil M, Wulfkuhle J, Fillmore H, Deng J, Liotta L, Petricoin E, Watson J, Broaddus W. Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2076 Background: Genome scanning analysis of human glioblastoma multiforme (GBM) has suggested that this form of cancer is a protein pathway disease. Since genomic analysis cannot directly predict protein activation, analysis of protein pathway activation is required. With the current focus on targeted translational therapeutic modalities, a functional understanding of the GBM signaling repertoire is critical, and yet largely unknown. Methods: Twelve tumors were included in this study: 10 GBMs (9 primary, 1 recurrent) and two brain metastases (1 breast and 1 lung). Pure tumor cell populations were obtained from fixed frozen tissue sections using Laser Capture Microdissection. Protein pathway mapping was performed using Reverse Phase Protein Microarrays (RPMA) whereby the activation of 85 key signaling proteins was quantitatively measured at once. Unsupervised and supervised analysis was used to explore pathway activation. Results: Unsupervised hierarchical clustering of all tumors in the study set revealed largely patient-specific signaling portraits yet also identified distinct pathway subsets. The two metastatic tumors clustered separately and distinctly from the GBMs. The GBM specimens clustered according to pathway activity. Statistical analysis demonstrated significant correlations between certain phosphorylated endpoints detected and overall survival. Phosphorylation of cofilin (S3) was associated with shorter survival time, while Stat1 (Y701) and Shc (Y317) phosphorylation were both positively correlated with longer overall survival. Conclusions: This study represents the most comprehensive proteomic analysis of human GBM pathway mapping to date. Since certain pathway biomarkers are themselves being targeted by current investigational therapies, the ability to map pathway activation and identify critical pathway biomarkers can lead to targeted therapeutics tailored to each patient's tumor. The ability to segregate short from long-term survivors according to protein pathway activation is promising. [Table: see text]
Collapse
Affiliation(s)
- M. Khalil
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - J. Wulfkuhle
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - H. Fillmore
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - J. Deng
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - L. Liotta
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - E. Petricoin
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - J. Watson
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| | - W. Broaddus
- George Mason University, Manassas, VA; Virginia Commonwealth University, Richmond, VA; Virginia Commonwealth University/Inova Campus, Falls Church, VA
| |
Collapse
|
27
|
Pierobon M, Silvestri A, Calvert V, Deng J, Belluco C, Nitti D, Colombatti A, Mammano E, Liotta L, Petricoin E. Use of a prognostic pathway signature for colorectal cancer comprised of EGFR/COX2 and imatinib drug target activation to predict occult metastasis in M0 CRC. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4042 Background: Development of distant metastasis is the main cause of death among CRC patients. Approximately 30% of CRC patients initially staged M0-N0 die from tumor recurrence. Previously, we determined that members of EGFR/PDGFR/cAbl/cKit pathways were hyperactivated in hepatic synchronous CRC metastasis compared to primary tumor. In order to determine if this signature was a distinguished repertoire of the early stage primary tumor, we analyzed 58 CRC M0 at the moment of the diagnosis that upon 5 yr follow-up had differing disease progressions. Methods: All tissues were immediately snap frozen after surgery. Reverse phase protein microarray (RPMA) was performed using microdissected material to generate multiplexed pathway profiling. For each sample 75 different endpoints were analyzed. Results: Statistical comparison of the 75 endpoints in 8 M0 patients who progressed to M1 and 50 patients who remained M0 regardless of initial staging, revealed a number of signaling proteins whose activation/phosphorylation were elevated and subsumed in a linked pathway. Specifically COX2 and c-Kit/PDGFR/Notch were highly activated in the 8 patients with occult metastasis. A prognostic pathway signature comprised of 13 interlinked molecules was developed. Univariate, ROC and Kaplan-Meier analysis of this signature revealed a statistically significant prognostic signature with an AUC of 0.87 and a 95% confidence interval. Conclusions: A signaling portrait of 13 interlinked proteins provided a strong prognostic indicator for metastasis regardless of stage. This signature was comprised of the phosphorylation/activation of growth factor receptors, including the entire suite of Gleevec targets. A large number of these prognostic signature components were previously found activated in the metastatic lesions themselves which indicates a potential functional role of this linked protein network in metastatic progression and maintenance. If validated in larger study sets, clinical trials to test Gleevec therapy combined with Cox2 /EGFR inhibitors to prevent/delay development of distant metastasis in patients with M0 should be considered. [Table: see text]
Collapse
Affiliation(s)
- M. Pierobon
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - A. Silvestri
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - V. Calvert
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - J. Deng
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - C. Belluco
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - D. Nitti
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - A. Colombatti
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - E. Mammano
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - L. Liotta
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| | - E. Petricoin
- George Mason University, Manassas, VA; CRO–IRCCS, National Cancer Institute, Aviano, Italy; University of Padua, Padova, Italy
| |
Collapse
|
28
|
Lanteri G, Marino F, Laganà G, Bellocco E, Barreca D, Liotta L, Sfacteria A, Macrì B. Acquired melanosis caused by acorn ingestion in the Nero Siciliano pig. Vet Pathol 2009; 46:329-33. [PMID: 19261647 DOI: 10.1354/vp.46-2-329] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In this study, an acquired pigmentation in Nero Siciliano pigs is reported and evaluated by a multidisciplinary approach to support the hypothesis it is caused by an ingested material. A total of 18 pigs were studied. Fourteen conventionally slaughtered animals showed black discoloration of lymph nodes. The lymph nodes were normal in size and shape but showed diffuse black discoloration of the cortex and medulla. Melanosis of fat was observed in 2 animals and was limited to the back. Histochemical tests performed on tissues enabled identification and differentiation of the pigment. Immunohistochemical staining for macrophage markers showed macrophages containing a variable amount of melanin-like granules. Stains for human melanoma, as well as S-100 protein, did not show any reaction. Histochemical methods for tyrosinase showed colorimetric patterns that confirmed the presence of the enzyme in acorns. The activity was mostly latent. A high tannin content was demonstrated, reaching about 76% of the total phenolic compounds. Our data, and the well-known steps on melanin formation, permit us to hypothesize that swine tyrosinase could act on phenolic substances found in acorns. Tyrosinase activation could take place in genetically predisposed swine after acorns are eaten, and this event could increase the biosynthesis and the anomalous storage of melanin.
Collapse
Affiliation(s)
- G Lanteri
- Dip. Sanità Pubblica Veterinaria, Università degli Studi di Messina, Polo Universitario dell'Annunziata, 98168 Messina, Italy
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Napoletani D, Sauer T, Struppa D, Petricoin E, Liotta L. Augmented sparse reconstruction of protein signaling networks. J Theor Biol 2008; 255:40-52. [DOI: 10.1016/j.jtbi.2008.07.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2007] [Revised: 07/19/2008] [Accepted: 07/21/2008] [Indexed: 11/16/2022]
|
30
|
Castro M, Papadatou B, Baldassare M, Balli F, Barabino A, Barbera C, Barca S, Barera G, Bascietto F, Berni Canani R, Calacoci M, Campanozzi A, Castellucci G, Catassi C, Colombo M, Covoni MR, Cucchiara S, D'Altilia MR, De Angelis GL, De Virgilis S, Di Ciommo V, Fontana M, Guariso G, Knafelz D, Lambertini A, Licciardi S, Lionetti P, Liotta L, Lombardi G, Maestri L, Martelossi S, Mastella G, Oderda G, Perini R, Pesce F, Ravelli A, Roggero P, Romano C, Rotolo N, Rutigliano V, Scotta S, Sferlazzas C, Staiano A, Ventura A, Zaniboni MG. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis 2008; 14:1246-52. [PMID: 18521916 DOI: 10.1002/ibd.20470] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND The purpose was to assess in Italy the clinical features at diagnosis of inflammatory bowel disease (IBD) in children. METHODS In 1996 an IBD register of disease onset was established on a national scale. RESULTS Up to the end of 2003, 1576 cases of pediatric IBD were recorded: 810 (52%) ulcerative colitis (UC), 635 (40%) Crohn's disease (CD), and 131 (8%) indeterminate colitis (IC). In the period 1996-2003 an increase of IBD incidence from 0.89 to 1.39/10(5) inhabitants aged <18 years was observed. IBD was more frequent among children aged between 6 and 12 years (57%) but 20% of patients had onset of the disease under 6 years of age; 28 patients were <1 year of age. Overall, 11% had 1 or more family members with IBD. The mean interval between onset of symptoms and diagnosis was higher in CD (10.1 months) and IC (9 months) versus UC (5.8 months). Extended colitis was the most frequent form in UC and ileocolic involvement the most frequent in CD. Upper intestinal tract involvement was present in 11% of CD patients. IC locations were similar to those of UC. Bloody diarrhea and abdominal pain were the most frequent symptoms in UC and IC, and abdominal pain and diarrhea in CD. Extraintestinal symptoms were more frequent in CD than in UC. CONCLUSIONS The IBD incidence in children and adolescents in Italy shows an increasing trend for all 3 pathologies. UC diagnoses exceeded CD.
Collapse
Affiliation(s)
- M Castro
- Ospedale Pediatrico Bambini Gesù, Roma, Italia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
D'Alessandro E, Fontanesi L, Liotta L, Davoli R, Chiofalo V, Russo V. Analysis of the MC1R gene in the Nero Siciliano pig breed and usefulness of this locus for breed traceability. Vet Res Commun 2007; 31 Suppl 1:389-92. [PMID: 17682921 DOI: 10.1007/s11259-007-0063-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- E D'Alessandro
- Department of Morphology, Biochemistry, Physiology and Animal Production, Section of Animal Production, Faculty of Veterinary Medicine, Messina, Italy.
| | | | | | | | | | | |
Collapse
|
32
|
Pierobon M, Calvert V, Lipsky M, Sheehan K, Speer R, Mammano E, Belluco C, Nitti D, Liotta L, Petricoin E. Personalized therapy for metastatic colorectal cancer: A closer possibility? J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4131 Background: Colorectal cancer (CRC) is the second leading cause of cancer related death in the Western world, and survival rate is closely associated with the development of metastases. Personalized targeted therapies promise to have a dramatic impact on the treatment of cancer over the next decade. The molecular fingerprint of a patient’s tumor is the basis for specific targeted therapy. Most often, we are not measuring what we are treating. If we choose therapy based on the primary tumor, but we are treating the metastasis, we are likely giving the wrong therapy if the two microenvironments are not equivalent. In this study we employed reverse phase protein microarrays (RPPA) to compare the protein kinases signal pathway derangements in the primary CRC and in its synchronous liver metastasis. Methods: Pure cell populations of 34 cases of patient-matched CRC and hepatic metastases (collected at the same surgical time) were isolated through laser capture microdissection and then lysed. The lysed cells were evaluated using RPPA technology that allowed us to analyze the activation status of 80 different kinases. Data analysis was performed using commercially available software. Results: Of the 80 kinases only 20 endpoints were significantly (p< 0.05) altered between the two populations. These endpoints were contained within just a few signaling pathways, including the PI3K-AKT prosurvival pathway and the c-kit/PDGFr/c-abl growth factor pathway. We noted a significant increase in phosphorylation of AKT along with a decrease in phosphorylation of PTEN in the liver metastasis compared to the matched primary tumors. This is in keeping with what is known about AKT since phosphorylation of PTEN serves to destabilize the protein, which serves as a natural upstream suppressor of AKT kinase. Conclusions: Specific cell signaling pathways, such as the PI3K-AKT and the c-kit/PDGFr/c-abl growth factor signaling pathway, are significantly altered and activated in hepatic metastasis compared to the primary colorectal site. Since the data reveals elevation in kinase activity increases on a pathway-wide level, a rational hypothesis can be developed whereby combinations of drugs such as an AKT- mTOR inhibitor and/or Gleevec may be an effective and novel therapeutic strategy for the treatment of metastatic CRC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Pierobon
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - V. Calvert
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - M. Lipsky
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - K. Sheehan
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - R. Speer
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - E. Mammano
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - C. Belluco
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - D. Nitti
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - L. Liotta
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| | - E. Petricoin
- George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; Padova University, Padova, Italy; Centro di Riferimento Oncologico, Aviano, Italy
| |
Collapse
|
33
|
Araujo R, Petricoin E, Liotta L. Mathematical Modeling of the Cancer Cell ’ s Control Circuitry: Paving the Way to Individualized Therapeutic Strategies. ACTA ACUST UNITED AC 2007. [DOI: 10.2174/157436207780619545] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
34
|
Liotta L, Chiofalo B, Lo Presti V, Piccolo D, Chiofalo V, Chiofalo V. Rosemary extract ( Rosmarinus officinalisL.) supplementation into the diet of Nero Siciliano pigs: effects on lipid oxidation. Italian Journal of Animal Science 2007. [DOI: 10.4081/ijas.2007.1s.306] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- L. Liotta
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - B. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - V. Lo Presti
- Consorzio di Ricerca Filiera Carni, Messina, Italy
| | - D. Piccolo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - V. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - V. Chiofalo
- Consorzio di Ricerca Filiera Carni, Messina, Italy
| |
Collapse
|
35
|
D’Alessandro E, Fontanesi L, Liotta L, Davoli R, Chiofalo V, Russo V. Nero Siciliano pig: analysis of coat colour affecting genes and perspectives for breed traceability. Italian Journal of Animal Science 2007. [DOI: 10.4081/ijas.2007.1s.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- E. D’Alessandro
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - L. Fontanesi
- Dipartimento di Protezione e Valorizzazione Agroalimentare, Università di Bologna, Italy
| | - L. Liotta
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - R. Davoli
- Dipartimento di Protezione e Valorizzazione Agroalimentare, Università di Bologna, Italy
| | - V. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali, Università di Messina, Italy
| | - V. Russo
- Dipartimento di Protezione e Valorizzazione Agroalimentare, Università di Bologna, Italy
| |
Collapse
|
36
|
Porcu S, Madonia G, Liotta L, Margiotta S, Chiofalo V, Ligios S. Physical characteristics of Longissimus lumborum muscle of “Sarda” and “Nero Siciliano” pigs reared outdoor. Preliminary results. Italian Journal of Animal Science 2007. [DOI: 10.4081/ijas.2007.1s.710] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- S. Porcu
- Istituto Zootecnico e Caseario per la Sardegna. Olmedo, Italy
| | - G. Madonia
- Istituto Sperimentale Zootecnico per la Sicilia. Palermo, Italy
| | - L. Liotta
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni animali. Università di Messina, Italy
| | - S. Margiotta
- Istituto Sperimentale Zootecnico per la Sicilia. Palermo, Italy
| | - V. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni animali. Università di Messina, Italy
| | - S. Ligios
- Istituto Zootecnico e Caseario per la Sardegna. Olmedo, Italy
| |
Collapse
|
37
|
D’Alessandro E, Liotta L, Pagliaro M, Chiofalo V. Influence of the feeding system on in vitam and post mortem performances of Nero Siciliano pigs. Italian Journal of Animal Science 2007. [DOI: 10.4081/ijas.2007.1s.683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- E. D’Alessandro
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
| | - L. Liotta
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
| | - M. Pagliaro
- Consorzio Ricerca Filiera Carni. Messina, Italy
| | - V. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni Animali. Università di Messina, Italy
- Consorzio Ricerca Filiera Carni. Messina, Italy
| |
Collapse
|
38
|
Madonia G, Porcu S, Liotta L, Margiotta S, Chiofalo V, Ligios S. Slaughter traits of “Sarda” and “Nero Siciliano” pigs reared outdoors. Preliminary results. Italian Journal of Animal Science 2007. [DOI: 10.4081/ijas.2007.1s.697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- G. Madonia
- Istituto Sperimentale Zootecnico per la Sicilia. Palermo, Italy
| | - S. Porcu
- Istituto Zootecnico e Caseario per la Sardegna. Olmedo (SS), Italy
| | - L. Liotta
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni animali. Università di Messina, Italy
| | - S. Margiotta
- Istituto Sperimentale Zootecnico per la Sicilia. Palermo, Italy
| | - V. Chiofalo
- Dipartimento di Morfologia, Biochimica, Fisiologia e Produzioni animali. Università di Messina, Italy
| | - S. Ligios
- Istituto Zootecnico e Caseario per la Sardegna. Olmedo (SS), Italy
| |
Collapse
|
39
|
Pierobon M, Calvert V, Lipsky M, Sheehan K, Speer R, Mammano E, Belluco C, Wulfkuhle J, Nitti D, Liotta L, Petricoin E. Alterations in molecular networks of metastatic colorectal carcinoma reveal organ-specific signatures: Implications for targeted therapy of metastatic disease. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3532 Background: Proteomic analysis of aberrant protein kinase activity is poised to provide crucial knowledge that could drive molecular-targeted therapeutics and personalized medicine. Many cancers are detected at late stages when metastasis has already occurred. Knowledge about the molecular derangements in the metastatic lesion is crucial for the rational selection of therapeutics. Very little is known about the signaling networks in the metastatic microenvironment. We employed reverse phase protein microarrays coupled to laser capture microdissection for a multiplexed phosphoproteomic fingerprint of colorectal metastatic disease to begin to understand the molecular functional changes that occur upon metastasis. Methods: 68 frozen cases of patient-matched colorectal cancer and hepatic metastasis, 15 cases of pulmonary metastasis, and 27 cases of hepatic metastasis of other primary cancers including breast, melanoma, pancreatic, ovarian, and stomach cancers (all taken at the same time at surgery), were subjected to laser capture microdissection. Procured tumor epithelia (20,000 cells per sample), were lysed and subjected to reverse phase protein microarray analysis. Using this technique, we measured the phosphorylation state of 75 kinase substrates. Molecular network analysis was performed using commercially available software. Results: Our results indicate that, unlike analysis of gene microarray data, we observe a significant difference between the molecular networks of activated kinase substrates within the metastatic lesion compared to the patient-matched primary tumor. In fact, despite overall patient-specific heterogeneity of the portraits, organ specific signatures that were independent of the primary origin of the tumor were identified. Conculsions: Effective treatment in the new era of personalized targeted therapeutics will require the ability to understand the functional activation of cellular signaling pathways since these are the drug targets themselves. Our results indicate that treatment of metastatic disease, and patient stratification for matching with the appropriate therapy may be organ-specific and not predicated upon the primary site of the disease. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Pierobon
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - V. Calvert
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - M. Lipsky
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - K. Sheehan
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - R. Speer
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - E. Mammano
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - C. Belluco
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - J. Wulfkuhle
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - D. Nitti
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - L. Liotta
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| | - E. Petricoin
- University of Padova, Padova, Italy; George Mason University, Manassas, VA; University of Maryland, Baltimore, MD; National Cancer Institute, Bethesda, MD; CRO Aviano Hospital, Aviano, Italy
| |
Collapse
|
40
|
Smith FM, Stephens R, Gaffney E, Crotty P, Petricoin E, Liotta L, Kennedy J, Reynolds J. Exploring the proteome as a response predictor for rectal cancer undergoing neoadjuvant radiochemotherapy (RCT). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. M. Smith
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - R. Stephens
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - E. Gaffney
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - P. Crotty
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - E. Petricoin
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - L. Liotta
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - J. Kennedy
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| | - J. Reynolds
- St James’s Hosp, Dublin, Ireland; Adelaide and Meath Hosp, Dublin, Ireland; National Cancer Institute, Bethesda, MD
| |
Collapse
|
41
|
|
42
|
|
43
|
Abstract
Diagnosis and management of cancer requires tools with both high sensitivity and specificity. The minimally invasive cervical smear has demonstrated how a test, even one with low specificity, can change the public health profile of a cancer from a late stage deadly disease to early diagnosis with rare tumor-related deaths. The benefit of such a test is best demonstrated by the low frequency of cervix cancer and its good outcome in countries where this test is readily available and used with appropriate secondary follow up. Early and specific symptoms, and identification and prevention for high risk groups has had similar impact for endometrial cancer. Neither a robust test, nor reliable or specific early symptoms are available for ovarian cancer, making clinical and scientific advances in this area a critical world-wide need. Current approaches testing one protein or gene marker at a time will not address this crisis expeditiously. New sensitive, specific, accurate, and reliable technologies that can be implemented using high throughput mechanisms are needed at as low a cost as possible. Ideally, these technologies should be focused on readily available patient resources, such as blood or urine, or as in the case of cervix cancer, minimally invasive informative approaches such as cervical smears. Techniques that allow data mining from a large input database overcome the slow advances of one protein-one gene investigation, and further address the multi-faceted carcinogenesis process occurring even in germ line mutation-associated malignancy. Proteomics, the study of the cellular proteins and their activation states, has led the progress in biomarker development for ovarian and other cancers and is being applied to management assessment. Amenable to high throughput, internet interface, and representative of the proteome spectrum, proteomic technology is the newest and most promising direction for translational developments in gynecologic cancers.
Collapse
Affiliation(s)
- E C Kohn
- Laboratory of Pathology, Gynecologic Malignancies Faculty, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
| | | | | |
Collapse
|
44
|
Martorana A, Deganello G, Longo A, Prestianni A, Liotta L, Macaluso A, Pantaleo G, Balerna A, Mobilio S. Structural evolution of Pt/ceria–zirconia TWC catalysts during the oxidation of carbon monoxide. J SOLID STATE CHEM 2004. [DOI: 10.1016/j.jssc.2003.11.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Chiofalo B, Liotta L, Zumbo A, Chiofalo L. Seasonal variations of free fatty acids in plasma of 'Nero Siciliano' pigs living in extensive conditions. Vet Res Commun 2003; 27 Suppl 1:253-5. [PMID: 14535403 DOI: 10.1023/b:verc.0000014153.61928.ec] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- B Chiofalo
- Department of Morphology, Biochemistry, Physiology and Animal Production, Section of Animal Production, Faculty of Veterinary Medicine, University of Messina, Polo Universitario Annunziata, Sicily, Italy.
| | | | | | | |
Collapse
|
46
|
Liotta L. Thermal stability, structural properties and catalytic activity of Pd catalysts supported on Al2O3–CeO2–BaO mixed oxides prepared by sol–gel method. ACTA ACUST UNITED AC 2003. [DOI: 10.1016/s1381-1169(03)00362-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Martorana A, Deganello G, Longo A, Deganello F, Liotta L, Macaluso A, Pantaleo G, Balerna A, Meneghini C, Mobilio S. Time-resolved X-ray powder diffraction on a three-way catalyst at the GILDA beamline. J Synchrotron Radiat 2003; 10:177-182. [PMID: 12606797 DOI: 10.1107/s0909049502019167] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2002] [Accepted: 10/17/2002] [Indexed: 05/24/2023]
Abstract
Time-resolved X-ray diffraction experiments carried out at the beamline BM08-GILDA of ESRF allowed a study of the structural modifications taking place in a Pt/ceria-zirconia catalyst while the CO oxidation reaction was in progress. The capillary tube in which the sample is stored acts effectively as a chemical microreactor that ensures homogeneity of the sample treatments and minimization of diffusion effects. During the flowing of the reactant CO/He mixture, the investigated catalyst undergoes a fast Ce(IV)-Ce(III) partial reduction that involves the release of one O atom for every two reduced Ce cations. Because Ce(III) has a larger ionic radius than Ce(IV), the structural modification produces an increase of the lattice constant of the ceria-zirconia mixed oxide, and this increase is monitored by the translating imaging-plate device implemented at GILDA. The CO(2) resulting from the oxidation of the fluxed CO is monitored by a quadrupole mass spectrometer during the recording of the time-resolved X-ray diffraction pattern. The chemical and structural information was combined to show that the CO(2) yield is nearly constant until the catalytic system can provide oxygen for the reaction, while the structural rearrangement of the catalyst is delayed with respect to the switching on of the CO/He flux. After this induction time, during which CO(2) is produced with no structural modification of the catalyst, a fast increase of the lattice constant takes place.
Collapse
Affiliation(s)
- A Martorana
- Dipartimento di Chimica Inorganica e Analitica Stanislao Cannizzaro, Università di Palermo, Viale delle Scienze, 90128 Palermo, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Coata G, Pennacchi L, Bini V, Liotta L, Di Renzo GC. Soluble adhesion molecules: marker of pre-eclampsia and intrauterine growth restriction. J Matern Fetal Neonatal Med 2002; 12:28-34. [PMID: 12422906 DOI: 10.1080/jmf.12.1.28.34] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVE This study monitored circulating plasma levels of soluble vascular cellular adhesion molecule-1 (sVCAM-1), intracellular adhesion molecule-1 (sICAM-1) and soluble E-selectin (sE-selectin) in women with healthy pregnancies, with pregnancy-induced hypertension (PIH), with pre-eclampsia and with pregnancies with isolated intrauterine growth restriction (IUGR) in order to determine whether elevated concentrations have a predictive value for the clinical signs of those pregnancy-induced disorders. METHODS Plasma concentrations of sVCAM-1, sICAM-1 and sE-selectin were determined in healthy pregnant women at each trimester of pregnancy and in pregnant women with PIH, pre-eclampsia and IUGR using commercial kits. RESULTS In the group of healthy pregnant women, plasma levels of sVCAM-1, sICAM-1 and sE-selectin did not change throughout pregnancy. No significant differences in the levels of these molecules were observed between healthy pregnant women at the third trimester of pregnancy and women with PIH. In addition, concentrations of soluble adhesion molecules were significantly higher in women with pre-eclampsia than in the group of women with healthy pregnancies. Only sVCAM-1 and sE-selectin levels were significantly higher in women with IUGR compared to healthy pregnant women. CONCLUSIONS Abnormally circulating levels of sVCAM-1, sICAM-1 and sE-selectin may have a predictive value for pre-eclampsia and IUGR, as they may be linked with endothelial activation and/or damage.
Collapse
Affiliation(s)
- G Coata
- Centre of Perinatal and Reproductive Medicine, Department of Gynecological, Obstetrical and Pediatric Sciences, University of Perugia, Italy
| | | | | | | | | |
Collapse
|
49
|
Hanash S, Petricoin E, Liotta L. A meeting of minds in proteomics. Proteomics 2001; 1:1475-8. [PMID: 11822353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
50
|
Zmuda JF, Wagoneer B, Liotta L, Whiteley G. Recognition of multiple classes of hepatitis C antibodies increases detection sensitivity in oral fluid. Clin Diagn Lab Immunol 2001; 8:1267-70. [PMID: 11687474 PMCID: PMC96260 DOI: 10.1128/cdli.8.6.1267-1270.2001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2001] [Accepted: 07/26/2001] [Indexed: 11/20/2022]
Abstract
Paired serum-oral fluid samples from 127 hepatitis C virus (HCV)-positive and 31 HCV-negative patients were tested for the presence of anti-HCV using the Ortho HCV 3.0 ELISA. Using the immunoglobulin G (IgG)-specific detection antibody provided with the HCV 3.0 ELISA we attained 100% sensitivity and specificity with serum samples; however, sensitivity in oral fluid samples was only 81%. By modifying the HCV 3.0 ELISA to utilize a secondary antibody cocktail that recognizes not only IgG but IgA and IgM as well, we attained 100% specificity and sensitivity with oral fluid samples.
Collapse
Affiliation(s)
- J F Zmuda
- Immunomatrix Inc., Gaithersburg, Maryland 20878, USA.
| | | | | | | |
Collapse
|